Ipratropiumbromid+fenoterolhydrobromid Farmak (Fenoterol Hydrobromide, Ipratropium Bromide Anhydrous)

Ipratropium bromide blocks muscarinic receptors, preventing acetylcholine‑induced bronchoconstriction, while fenoterol hydrobromide activates β2‑adrenergic receptors, increasing cyclic AMP and causing smooth‑muscle relaxation. Together they produce additive bronchodilation, rapidly improving airflow in obstructive lung conditions.

The prescribed dose of Ipratropiumbromid+fenoterolhydrobromid Farmak is determined by the treating physician based on the patient’s age, severity of disease and response to therapy. Dosage instructions are provided on the prescription label and should be followed exactly as directed by the healthcare professional.

Safety data for ipratropium bromide and fenoterol hydrobromide during pregnancy and lactation are limited. The drug should be used only if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made in consultation with a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the team provides pricing, availability, shipping details (including any cold‑chain requirements) and assists with import documentation.

The ipratropium‑fenoterol combination offers dual mechanisms—anticholinergic and β2‑agonist—in a single inhalation solution, providing broader bronchodilation than either agent alone. Compared with single‑component inhalers, the combo may reduce the number of devices a patient needs, potentially improving adherence while delivering rapid symptom relief.

Store the inhalation solution at room temperature, below 25 °C, in its original packaging. Keep the container tightly closed, protect it from moisture and direct sunlight, and avoid freezing. Follow any additional handling instructions on the label to maintain product stability.

The product is supplied as an inhalation solution intended for use with a compatible nebulizer or inhalation device. The patient inhales the aerosolized medication as directed by the prescriber, typically multiple times per day or during acute episodes, ensuring the mouthpiece is clean and the device is operated according to the manufacturer’s guidelines.

Serious adverse reactions, although rare, include paradoxical bronchospasm, angioedema, severe tachyarrhythmia and anaphylactic reactions. Patients should seek immediate medical attention if they experience sudden worsening of breathing, swelling of the face or throat, rapid heart rate, or signs of an allergic reaction.

The medication is contraindicated in individuals with known hypersensitivity to ipratropium bromide, fenoterol hydrobromide, or any excipients in the formulation. It should also be avoided in patients with a history of severe paradoxical bronchospasm or those for whom β2‑agonists are contraindicated, such as certain cardiac arrhythmia conditions, unless specifically advised by a physician.